Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

RCT-TCZ-COVID-19, 2021
 
NCT04346355
RCTtocilizumab standard of careCOVID 19 hospitalizedsome concern
60/66 inconclusive
    Colaneri, 2020 OBStocilizumab controlCOVID 19 hospitalizedcritical
    21/21 inconclusive
      HNF Hospital Tocilizumab multidisciplinary team, 2020 OBStocilizumab controlCOVID 19 hospitalizedcritical
      20/25 suggested
      • suggested 87 % decrease in death or transfer to ICU but with a very low degree of certainty due to critical risk of bias
      Martinez-Sanz, 2020 OBStocilizumab controlCOVID 19 hospitalizedcritical
      260/969 suggested
      • suggested 66 % decrease in deaths but with a very low degree of certainty due to critical risk of bias
      Tsai, 2020 OBStocilizumab controlCOVID 19 hospitalizedserious
      66/66 inconclusive

        COVID-19 mild to moderate meta-analysis

        CORIMUNO-19, 2020
         
        NCT04331808
        RCTtocilizumab standard of careCOVID-19 mild to moderatesome concern
        64/67 inconclusive
          EMPACTA, 2020
           
          NCT04372186
          RCTtocilizumab placeboCOVID-19 mild to moderatesome concern
          259/129 conclusif
          • demonstrated 44 % decrease in death or ventilation (PE) with a moderate degree of certainty due to some concern in risk of bias
          • suggested 45 % decrease in clinical deterioration with a moderate degree of certainty due to some concern in risk of bias
          Capra, 2020 OBStocilizumab controlCOVID-19 mild to moderatecritical
          62/23 suggested
          • suggested 96 % decrease in deaths,deaths (time to event analysis only) but with a very low degree of certainty due to critical risk of bias

          COVID-19 severe or critically meta-analysis

          REMAP-CAP tocilizumab, 2021
           
          NCT02735707
          RCTtocilizumab standard of careCOVID-19 severe or criticallysome concern
          353/402 conclusif
          • suggested 30 % decrease in deaths with a moderate degree of certainty due to some concern in risk of bias
          • demonstrated 64 % increase in clinical improvement (PE) with a moderate degree of certainty due to some concern in risk of bias
          BACC Bay Tocilizumab Trial, 2020
           
          NCT04356937
          RCTtocilizumab placeboCOVID-19 severe or criticallylow
          161/81 inconclusive
          • inconclusive 17 % decrease in death or ventilation (PE) with a high degree of certainty due to low risk of bias
          COVACTA (Rosas), 2020
           
          NCT04320615
          RCTtocilizumab placeboCOVID-19 severe or criticallysome concern
          294/144 inconclusive
            Andrew, 2020 OBStocilizumab controlCOVID-19 severe or criticallyNA
            198/413 inconclusive
              Biran, 2020 OBStocilizumab controlCOVID-19 severe or criticallyserious
              210/420 suggested
              • suggested 36 % decrease in deaths but with a low degree of certainty due to high risk of bias
              Mathilde, 2020 OBStocilizumab controlCOVID-19 severe or criticallycritical
              30/29 suggested
              • suggested 75 % decrease in deaths but with a very low degree of certainty due to critical risk of bias
              Rojas-Marte, 2020 OBStocilizumab controlCOVID-19 severe or criticallycritical
              96/97 inconclusive
                Somers, 2020 OBStocilizumab controlCOVID-19 severe or criticallycritical
                78/76 safety concern
                • suggested 45 % decrease in deaths,deaths (time to event analysis only) but with a very low degree of certainty due to critical risk of bias
                • statistically significant 2.3-fold increase in superinfection but with a very low degree of certainty due to critical risk of bias
                TOCI-RAF Study Group (Campochiaro), 2020 OBStocilizumab controlCOVID-19 severe or criticallyNA
                32/33 inconclusive

                  PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
                  Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).